VLDLR and atherosclerosis: Similarly, high plasma levels of Lp(a) accelerated the progression of atherosclerosis among ESKD patients via low-density lipoprotein receptor (LDLr) and membrane-bound CXC chemokine ligand 16 (CXCL16)-associated Lp(a) accumulation in arteries [21].